This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Molecular Pathogenesis of Mantle Cell Lymphoma - p. 795 9. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy - p. 809 10. What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - p. 825 11. Watch and Wait in Mantle Cell Lymphoma - p. 837 12. Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed? - p. 849 13. Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma - p. 861 14. Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma - p. 871 15. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance - p. 887 16. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma - p. 903 17. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients? - p. 923 18. Blastoid Mantle Cell Lymphoma - p. 941 19. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma - p. 957 20. Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma - p. 971 21. Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma - p. 983
This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Molecular Pathogenesis of Mantle Cell Lymphoma - p. 795 9. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy - p. 809 10. What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes? - p. 825 11. Watch and Wait in Mantle Cell Lymphoma - p. 837 12. Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed? - p. 849 13. Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma - p. 861 14. Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma - p. 871 15. Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance - p. 887 16. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma - p. 903 17. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients? - p. 923 18. Blastoid Mantle Cell Lymphoma - p. 941 19. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma - p. 957 20. Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma - p. 971 21. Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma - p. 983
